Endocrinology , 158 (5), 10491063
In both the Asian and non-Asian patients subgroups, oral semaglutide 3, 7, and 14 mg was more effective in reducing HbA1c than placebo, and between-subgroups analysis showed that semaglutide 3, 7, and 14 mg was more effective in reducing HbA1c in the Asian patients subgroup than in the non-Asian patients subgroup
MedlinePlus.gov National Geographic
Focusing on SIRT3, recent studies indicate that its activation is generally protective
In contrast, another GLP1R agonist , with a shorter half-life of around 13 hours (Liraglutide) achieved only 5.5% reduction in the same time span [22] , demonstrating that improving half-life can result in better outcomes